关于癌症化疗耐药性的一些思考。 - Suppr

Suppr

超能文献

Some thoughts on resistance to cancer chemotherapy.

作者信息

Carter S K

出版信息

Cancer Treat Rev. 1984 Mar;11 Suppl A:3-7. doi: 10.1016/0305-7372(84)90037-9.

DOI:10.1016/0305-7372(84)90037-9

PMID:6375863

Abstract

摘要

相似文献

Some thoughts on resistance to cancer chemotherapy.

Cancer Treat Rev. 1984 Mar;11 Suppl A:3-7. doi: 10.1016/0305-7372(84)90037-9.

The forty-year-old mutation theory of Luria and Delbrück and its pertinence to cancer chemotherapy.

Adv Cancer Res. 1983;40:331-63. doi: 10.1016/s0065-230x(08)60683-1.

The use of cell kinetics in the development of drug combinations.

Pharmacol Ther. 1979;4(1):1-33. doi: 10.1016/0163-7258(79)90013-5.

Clinical aspects of drug resistance.

Antibiot Chemother (1971). 1978;23:238-46. doi: 10.1159/000401487.

Rationale for the use of alternating non-cross-resistant chemotherapy.

Cancer Treat Rep. 1982 Mar;66(3):439-49.

New thoughts on resistance to chemotherapy.

Hosp Pract (Off Ed). 1983 May;18(5):165-9, 173-7. doi: 10.1080/21548331.1983.11702548.

Cancer chemotherapy. The relevance of certain concepts of cell cycle kinetics.

Biochim Biophys Acta. 1978 Dec 11;516(4):389-417. doi: 10.1016/0304-419x(78)90018-5.

The experimental basis for combination chemotherapy.

Cancer Treat Rev. 1984 Mar;11 Suppl A:19-23. doi: 10.1016/0305-7372(84)90039-2.

Combination chemotherapy--theory and practice.

Semin Oncol. 1977 Jun;4(2):227-53.

Clinical concepts derived from animal chemotherapy studies.

Cancer Treat Rep. 1981;65 Suppl 3:11-9.

引用本文的文献

Mechanisms and Therapeutic Advances of PXR in Metabolic Diseases and Cancer.

Int J Mol Sci. 2025 Aug 20;26(16):8029. doi: 10.3390/ijms26168029.

PCK1-mediated glycogenolysis facilitates ROS clearance and chemotherapy resistance in cervical cancer stem cells.

Sci Rep. 2024 Jun 13;14(1):13670. doi: 10.1038/s41598-024-64255-6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Some thoughts on resistance to cancer chemotherapy.

Cancer Treat Rev. 1984 Mar;11 Suppl A:3-7. doi: 10.1016/0305-7372(84)90037-9.

The forty-year-old mutation theory of Luria and Delbrück and its pertinence to cancer chemotherapy.

Adv Cancer Res. 1983;40:331-63. doi: 10.1016/s0065-230x(08)60683-1.

The use of cell kinetics in the development of drug combinations.

Pharmacol Ther. 1979;4(1):1-33. doi: 10.1016/0163-7258(79)90013-5.

Clinical aspects of drug resistance.

Antibiot Chemother (1971). 1978;23:238-46. doi: 10.1159/000401487.

Rationale for the use of alternating non-cross-resistant chemotherapy.

Cancer Treat Rep. 1982 Mar;66(3):439-49.

New thoughts on resistance to chemotherapy.

Hosp Pract (Off Ed). 1983 May;18(5):165-9, 173-7. doi: 10.1080/21548331.1983.11702548.

Cancer chemotherapy. The relevance of certain concepts of cell cycle kinetics.

Biochim Biophys Acta. 1978 Dec 11;516(4):389-417. doi: 10.1016/0304-419x(78)90018-5.

The experimental basis for combination chemotherapy.

Cancer Treat Rev. 1984 Mar;11 Suppl A:19-23. doi: 10.1016/0305-7372(84)90039-2.

Combination chemotherapy--theory and practice.

Semin Oncol. 1977 Jun;4(2):227-53.

Clinical concepts derived from animal chemotherapy studies.

Cancer Treat Rep. 1981;65 Suppl 3:11-9.

引用本文的文献

Mechanisms and Therapeutic Advances of PXR in Metabolic Diseases and Cancer.

Int J Mol Sci. 2025 Aug 20;26(16):8029. doi: 10.3390/ijms26168029.

PCK1-mediated glycogenolysis facilitates ROS clearance and chemotherapy resistance in cervical cancer stem cells.

Sci Rep. 2024 Jun 13;14(1):13670. doi: 10.1038/s41598-024-64255-6.